ArticleMolecular medicine (Cambridge, Mass.)2025
GPR43 regulates mitochondrial apoptosis through the cyclophilin D pathway in Alzheimer's disease.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting FCRLA to induce necrosis in lung adenocarcinoma: a novel strategy for prognosis and therapy via MPT-Driven pathways.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundG protein-coupled receptor 43 (GPR43) is a critical signaling molecule involved in maintaining energy balance and immune homeostasis, making it a widely studied drug target. However, its role in Alzheimer’s disease (AD) remains unclear. This study aims to investigate the effects of GPR43 activation in an Aβ1−42-induced AD mouse model and to elucidate the underlying mechanisms.
methodsExperiments were performed using Aβ1-42-induced C57BL/6 mice (in vivo model) and the mouse hippocampal neuronal cell line HT22 (in vitro model). GPR43 gene expression and protein levels were analyzed in the brains of AD mice. Lentivirus-mediated GPR43 overexpression was employed to assess its effects on AD-like behaviors and pathological features. Cyclosporin A (CSA), a cyclophilin D (CypD) inhibitor, was used to investigate the pathological mechanisms of GPR43 in AD.
resultCompared to wild-type mice, GPR43 expression was downregulated in the cerebral cortex and hippocampus of Aβ1-42-induced AD mice and was primarily localized to neurons. GPR43 activation improved spatial learning and memory in AD mice. Furthermore, it upregulated the expression of brain-derived neurotrophic factor (BDNF), postsynaptic density protein 95 (PSD95), and synaptophysin (SYP), indicating enhanced neuronal and synaptic function. GPR43 upregulation also modulated the levels of mitochondrial damage-related enzymes, including superoxide dismutase (SOD), malondialdehyde (MDA), and lactate dehydrogenase (LDH) levels, and reduced mitochondrial swelling. Notably, GPR43 downregulated CypD protein levels, which are linked to mitochondrial permeability transition pore (mPTP) channels, thereby inhibiting apoptosis. Finally, in GPR43-knockdown cells, treatment with CSA significantly reduced the apoptosis rate, decreased BAX and Caspase-9 levels, and increased BCL-2 expression.
conclusionGPR43 inhibits apoptosis in AD mice through the CypD signaling pathway, highlighting its potential as a novel target for drug development in AD treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.